Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

References

  1. Lanier LL . Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008; 9: 495–502.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999; 285: 727–729.

    Article  CAS  PubMed  Google Scholar 

  3. Nausch N, Cerwenka A . NKG2D ligands in tumor immunity. Oncogene 2008; 27: 5944–5958.

    Article  CAS  PubMed  Google Scholar 

  4. von Strandmann EP, Hansen HP, Reiners KS, Schnell R, Borchmann P, Merkert S et al. A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood 2006; 107: 1955–1962.

    Article  PubMed  Google Scholar 

  5. Weng WK, Levy R . Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21: 3940–3947.

    Article  CAS  PubMed  Google Scholar 

  6. van der Veer MS, de Weers M, van Kessel B, Bakker JM, Wittebol S, Parren PW et al. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica 2010; 96: 284–290.

    Article  PubMed  PubMed Central  Google Scholar 

  7. de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011; 186: 1840–1848.

    Article  CAS  PubMed  Google Scholar 

  8. Wu J, Song Y, Bakker AB, Bauer S, Spies T, Lanier LL et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 1999; 285: 730–732.

    Article  CAS  PubMed  Google Scholar 

  9. Billadeau DD, Upshaw JL, Schoon RA, Dick CJ, Leibson PJ . NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway. Nat Immunol 2003; 4: 557–564.

    Article  CAS  PubMed  Google Scholar 

  10. Inagaki A, Ishida T, Yano H, Ishii T, Kusumoto S, Ito A et al. Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC. Int J Cancer 2009; 125: 212–221.

    Article  CAS  PubMed  Google Scholar 

  11. Cho HM, Rosenblatt JD, Tolba K, Shin SJ, Shin DS, Calfa C et al. Delivery of NKG2D ligand using an anti-HER2 antibody-NKG2D ligand fusion protein results in an enhanced innate and adaptive antitumor response. Cancer Res 2010; 70: 10121–10130.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by research Grant 2007.065.1 from the Wilhelm Sander Stiftung, Neustadt, Germany, research Grant DJCLS R 08/01 from the Deutsche José Carreras Leukämie Stiftung e.v., and intramural funding from the Christian-Albrechts-University Kiel. We thank Anja Muskulus, Britta von Below and Heidi Bosse for expert technical assistance. Sahar Mohseni Nodehi was supported by the FAZIT-Stiftung (Frankfurt am Main, Germany).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M Peipp.

Ethics declarations

Competing interests

M de Weers, PWHI Parren and JGJ van de Winkel are employees of Genmab. The remaining authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kellner, C., Hallack, D., Glorius, P. et al. Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity. Leukemia 26, 830–834 (2012). https://doi.org/10.1038/leu.2011.288

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2011.288

This article is cited by

Search

Quick links